---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015083"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:42:30.748698+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q1 net loss $10.1M; FDA clears percutaneous electrode; plans $60M rights offering

## Summary
- FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for soft tissue ablation in percutaneous and intraoperative procedures.
- CellFX nsPFA Cardiac Clamp 510(k) process ongoing; FDA requests clinical data; feasibility study submitted in Netherlands.
- Board approved rights offering of up to $60M in units; record date moved to mid-June; fully subscribed adds $66M warrants.
- GAAP net loss Q1 2024 $10.1M vs $9.8M year ago; cash $34.9M (down from $44.4M Dec 31, 2023).
- Non-GAAP net loss $8.1M vs $8.6M prior year; Q1 cash used $9.5M including $2M annual bonus payouts.

## SEC filing metadata
- accession: 0001437749-24-015083
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/0001437749-24-015083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/plse20240321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015083
- JSON: https://secwatch.observer/filing/0001437749-24-015083.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015083.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2024 results: net income GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon.
  - Period: the first quarter ended March 31, 2024
  - Net income: GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon
  - Result: reported results
  source text: Pulse Biosciences, Inc. (the "Company") announced its financial and operational results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/0001437749-24-015083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.